Showing results (611-620 of 1,609) with videos related to

Sort By:
Pageof 161
JAMA Oncology|November 24, 2021
Outcomes of Screening for Prostate Cancer Among Men Who Use StatinsArla Vettenranta, Teemu J Murtola, Jani Raitanen, et al.
JAMA Oncology|January 6, 2022
Association of Daily Sitting Time and Leisure-Time Physical Activity With Survival Among US Cancer SurvivorsChao Cao, Christine M Friedenreich, Lin Yang
JAMA Oncology|January 20, 2022
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging AnalysisLaurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
JAMA Oncology|November 4, 2021
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic StudiesSamantha Brown, Jessica A Lavery, Ronglai Shen, et al.
JAMA Oncology|December 9, 2021
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 DecadesSophia C Kamran, Andrzej Niemierko, Curtiland Deville, et al.
JAMA Oncology|December 30, 2021
Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical TrialXiangyun Zong, Yang Yu, Hongjian Yang, et al.
JAMA Oncology|December 30, 2021
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019, Jonathan M Kocarnik, Kelly Compton, et al.
JAMA Oncology|October 13, 2022
Association of Changes in Cancer Therapy Over 3 Decades With Risk of Subsequent Breast Cancer Among Female Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study (CCSS)Tara O Henderson, Qi Liu, Lucie M Turcotte, et al.
JAMA Oncology|September 1, 2022
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical TrialThierry Conroy, Florence Castan, Anthony Lopez, et al.
JAMA Oncology|September 1, 2022
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical TrialNizar M Tannir, Neeraj Agarwal, Camillo Porta, et al.
Pageof 161